DT120 (MM120): a single-dose orally disintegrating formulation of lysergide tartrate for generalized anxiety disorder.

Abstract

<h4>Introduction</h4>Generalized anxiety disorder (GAD) is a chronic, disabling condition for which currently available pharmacotherapies have delayed onset, incomplete remission rates, treatment-emergent adverse effects and substantial real-world discontinuation. DT120, formerly MM120, is an investigational orally disintegrating tablet formulation of lysergide tartrate being developed as a single-dose treatment for GAD.<h4>Areas covered</h4>This drug profile evaluates the GAD treatment landscape, DT120 nomenclature and formulation, lysergide pharmacology, the phase 2b MM120 efficacy and safety data, the ongoing phase 3 Voyage and Panorama programs, regulatory considerations and requirements for clinical implementation. PubMed, Embase, ClinicalTrials.gov, regulatory guidance and public sponsor disclosures were reviewed through to the 14^th of September 2026.<h4>Expert opinion</h4>The phase 2b dose-finding study provides a credible signal of rapid and durable anxiolytic activity after one 100 microgram administration without protocol-mandated psychotherapy. However, DT120 should not be described as microdosing or modified release: 100 micrograms is a perceptible psychedelic dose, whereas controlled microdosing studies have generally used 5-20 micrograms, and the pivotal product is described publicly as a fast-dissolving orally disintegrating tablet. Adoption will depend on full peer-reviewed reporting of the positive Voyage and Panorama phase 3 topline results, formulation bridging, durability and retreatment data, management of functional unblinding, and a scalable monitored-care model.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

Keywords